Results 21 to 30 of about 650,104 (308)

Mitoribosome sensitivity to HSP70 inhibition uncovers metabolic liabilities of castration-resistant prostate cancer. [PDF]

, 2023
The androgen receptor is a key regulator of prostate cancer and the principal target of current prostate cancer therapies collectively termed androgen deprivation therapies.
Shrimp, Jonathan H, Maisiak, M, Gestwicki, JE, Nisbet, Ian, Jonathan H Shrimp, Ralph, SJ, Jason E Gestwicki, Murali Krishna Cherukuri, Cherukuri, Murali Krishna, Cherukuri, MK, Shrimp, JH, Marisa Maisiak, Neckers, Leonard M, Maisiak, Marisa, Genesis M Rivera-Marquez, Oleta T Johnson, Ishida, R, Johnson, OT, Echtenkamp, FJ, Rivera-Marquez, Genesis M, Ryo Ishida, Leonard M Neckers, Ishida, Ryo, Sinha, Arnav, Rivera-Marquez, GM, Ralph, Stephen John, Gestwicki, Jason E, Echtenkamp, Frank J, Johnson, Oleta T, Frank J Echtenkamp, Sinha, A, Stephen John Ralph, Ian Nisbet, Nisbet, I, Arnav Sinha, Neckers, LM   +35 more
core   +1 more source

Calcium phosphate-based nanomedicine mediated CRISPR/Cas9 delivery for prostate cancer therapy

Frontiers in Bioengineering and Biotechnology, 2022
Introduction: Erythropoietin producing hepatocyte receptor A2 (EphA2) is widely presented in the tumor cells, closely related to tumor cell migration, not cell apoptosis and proliferation.
Chao-Gang Wei, Rui Zhang, Lan-Yi Wei, Peng Pan, He Zu, Ya-Zhen Liu, Yong Wang, Jun-Kang Shen   +7 more
doaj   +1 more source

Epiregulin expression and secretion is increased in castration-resistant prostate cancer. [PDF]

, 2023
INTRODUCTION In prostate cancer, long-term treatment directed against androgens often leads to the development of metastatic castration-resistant prostate cancer, which is more aggressive and not curatively treatable.
Wiesehöfer, Caroline, Wiesehöfer, Marc, Czyrnik, Elena Dilara, Wennemuth, Gunther, Raczinski, Benedikt Bernhard Gereon, Spahn, Martin, Dankert, Jaroslaw Thomas, Kruithof-de Julio, Marianna   +7 more
core   +1 more source

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. [PDF]

, 2013
BACKGROUND: Standard medical castration reduces muscle mass. We sought to characterize body composition changes in men undergoing maximal androgen suppression with and without exogenous gluocorticoids.
J S de Bono, Pezaro, C., Cassidy, A.M., de Bono, J.S., Pezaro, C, Seed, G., Mukherji, D, de Bono, JS, Omlin, A, Tunariu, N., N Tunariu, G Attard, D Olmos, Attard, G, G Seed, Reid, A.H.M., Seed, G, Mukherji, D., A M Cassidy, Bianchini, D., Cassidy, AM, Olmos, D., A H M Reid, Attard, G., A Omlin, D Bianchini, D Mukherji, Tunariu, N, Olmos, D, Reid, AHM, C Pezaro, Bianchini, D, Omlin, A.   +32 more
core   +1 more source

Resistance to “Castration-Resistant” [PDF]

The Oncologist, 2014
The author challenges the use of the phrase “castration resistance,” which is widely used in the literature and also appears in a recent article by Merseburger et al.
openaire   +2 more sources

Knowledge mapping of immunotherapy in castration-resistant prostate cancer: a bibliometric and visualized study (2003–2022)

Frontiers in Urology, 2023
ObjectiveTo utilize bibliometric analysis to examine the literature about immunotherapy for castration-resistant prostate cancer published within the past two decades.
Xianfu Cai, Xianfu Cai, Chenguang Ding, Yang Li, Jin Zheng, Wujun Xue   +5 more
doaj   +1 more source

Castrate-resistant prostate cancer [PDF]

Current Opinion in Urology, 2013
Prior to 2010, docetaxel was the only treatment shown to prolong survival in metastatic castrate-resistant prostate cancer (CRPC). In the past 3 years, several therapeutic agents have demonstrated survival improvements for CRPC after the receipt of prior docetaxel, leading to multiple approvals by the US Food and Drug Administration.The development of ...
Song, Zhao, Evan Y, Yu
openaire   +2 more sources

Utility of plasma cell‐free DNA in metastatic castration‐resistant prostate cancer

IJU Case Reports, 2020
Introduction Cell‐free DNA is suggested as a prognostic biomarker in metastatic castration‐resistant prostate cancer. However, it remains unknown which parameter of cell‐free DNA is correlated with the progression and prognosis of metastatic castration ...
Itsuto Hamano, Shingo Hatakeyama, Tomoko Hamaya, Kyo Togashi, Teppei Okamoto, Hayato Yamamoto, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama   +9 more
doaj   +1 more source

Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer

Scientific Reports, 2023
Prostate cancer is the most prevalent cancer in men worldwide and is promoted by the sex hormone androgen. Expression of androgen from the testis can be significantly reduced through castration.
Won Sik Shin, Seung Hyun Han, Kyung Won Jo, Yunje Cho, Kyong-Tai Kim   +4 more
doaj   +1 more source

Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors’ experience

Медицинский совет, 2021
Prostate cancer is one of the most common neoplasms in men. It currently ranks second in Russian Federation amongst male population in overall number of cases after only lung cancer and third in cancer mortality.
T. V. Ustinova, L. V. Bolotina, A. A. Paichadze, A. A. Kachmazov, A. A. Fedenko, A. D. Kaprin   +5 more
doaj   +1 more source